Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2005
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171143 selective Chemoattractant receptor-homologous molecule expressed on Th2 cells ( CRTH2 receptor) antagonist; activities for eosinphil and basophil infiltration; indol/carbazol-sulfonamide derivatives; antiallergenic agent; asthma, allergic rhinitis and dermatitis, polyarteritis, autoimmune disease
08/04/2005US20050171134 such as 4-[4-(1-Amino-1-methylethyl)phenyl]-5-chloro-N-[4-(2-hydroxyethyl)phenyl]pyrimidine-2-amine used as tyrosine kinase inhibitors, for prophylaxis disease states associated with angiogenesis
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171123 Quinazoline derivatives as medicaments
08/04/2005US20050171122 Mitotic kinesin inhibitors
08/04/2005US20050171118 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
08/04/2005US20050171117 Preparation of pharmaceutical salts
08/04/2005US20050171113 Product comprising an inhibitor of the transduction of heterotrimeric G protein signals combined with an anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171106 5'-((benzo)thiophen-1 or 2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] compounds, optionally tritium labeled; binding ligands for nicotinic acetylcholine receptors
08/04/2005US20050171104 Novel thyroid receptor ligands
08/04/2005US20050171103 Benzamide derivatives useful as histone deacetylase inhibitors
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171098 MCH antagonists and their use in the treatment of obesity
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171094 Pyrrolopyrimidine derivatives
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171091 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
08/04/2005US20050171087 high affinity agonists; high specificity; side effect reduction; endometriosis; hormone dependent cancers, fertility control; dibenzo[b,f]pyrido[1,2-d][1,4] oxazepin, dibenzo[b,f]pyrido[1,2-d][1,4]thiazepim, dibenzo[b,f]pyrido[1,2-d][1,4]diazepin and dibenzo[c,f]pyrido[1,2-a]azepine derivatives
08/04/2005US20050171083 Modified release pharmaceutical formulation
08/04/2005US20050171078 Cholinergic ligands at the nicotinic acetylcholine receptors; diseases related to the cholinergic system; neurodegenerative disorders; pain; antiinflammatory; diagnostic or monitoring tools using labelled forms; 3-Phenyletynyl-quinuclidin-2-ene
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171060 Anticancer agents and drug delivery agents with nucleotides
08/04/2005US20050171059 Silanol enzyme inhibitors
08/04/2005US20050171050 Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine
08/04/2005US20050171049 Compounds for the treatment of ischemia
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050171036 antitumor and anticarcinogenic agent; topoisomerase I inhibitor; synergistic effect by targeting different types of enzymes; low toxicity
08/04/2005US20050171024 Modulating angiogenesis
08/04/2005US20050171007 Therapeutic method
08/04/2005US20050170504 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
08/04/2005US20050170449 Soluble GlcNAc phosphotransferase
08/04/2005US20050170408 Recombinant g protein coupled receptor for use in identifying modulators for prevention and treatment of cell proliferative disorders
08/04/2005US20050170364 Novel human kinase protein and polynucleotides encoding the same
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050170327 Isolating thrombocytes from whole blood via agglutinating and sedimenting erthrocytes; regenerative medicine; tisssue engineering
08/04/2005US20050170007 Ude of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix
08/04/2005US20050169983 Chewable soft capsule
08/04/2005US20050169982 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability
08/04/2005US20050169971 Pellet or tablet attractive to livestock masking a drug such as benazepril; animal feed substrate, intimately mixed with coated particles of a carrier material and an active ingredient casing that is coated by a masking protective layer
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169922 drug screening for compounds that enhance or suppress killer T cell activity by contacting killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005CA2552763A1 Method of treating type iii hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
08/04/2005CA2495839A1 Anti-photoaging cosmeceutical composition
08/03/2005EP1559780A1 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
08/03/2005EP1559726A2 Growth differentiation factor-10
08/03/2005EP1559716A1 Pyrazolonaphthyridine derivative
08/03/2005EP1559715A1 N-[2-chloro-4-(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
08/03/2005EP1559710A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
08/03/2005EP1559709A1 Heterocycle-containing carboxylic acid derivative and drug containing the same
08/03/2005EP1559708A1 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE
08/03/2005EP1559707A1 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
08/03/2005EP1559446A1 Treating agent for diarrhea-predominant irritable bowel syndrome
08/03/2005EP1559428A1 Receptor regulator
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1559321A1 Mixed compositions for controlling parasitic insects
08/03/2005EP1558610A2 Substituted aminoquinuclidine compounds and their use as delta-opioid receptor ligands
08/03/2005EP1558577A2 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
08/03/2005EP1558256A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
08/03/2005EP1558252A2 Substituted furo 2,3-b] pyridine derivatives
08/03/2005EP1438307B1 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist
08/03/2005EP1418937A4 Enhancing organ maturity in neonates and predicting their duration of intensive care
08/03/2005EP1399446B1 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
08/03/2005EP1392347B1 Preventing cell death using segments of neural thread proteins
08/03/2005EP1330455B1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
08/03/2005EP1330166B1 Food grade transglutaminase inhibitor and uses thereof
08/03/2005EP1228059B1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
08/03/2005EP1225896B1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors
08/03/2005EP1142890B1 Aminopyrazole derivatives
08/03/2005EP1140173B1 Vascular endothelial cell growth factor antagonists and uses thereof
08/03/2005EP0851925B1 Human growth hormone variants
08/03/2005EP0815231B1 Use of neuronal apoptosis inhibitor protein (naip)
08/03/2005EP0755259B1 CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON
08/03/2005EP0742834B2 Method of preparing a viral vector of at least 20kb by intermolecular recombination in a procaryotic cell
08/03/2005CN1650169A Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
08/03/2005CN1650020A Means and methods for the production of adenovirus vectors
08/03/2005CN1650014A Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
08/03/2005CN1649895A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
08/03/2005CN1649893A Dipeptide derivatives having a N-terminal 2-thiocyl group as vasopeptidase inhibitors
08/03/2005CN1649885A Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
08/03/2005CN1649884A Novel azacyclic ethynyl derivatives
08/03/2005CN1649883A Bicyclic 6-alkylidene-penems as lactamases inhibitors
08/03/2005CN1649882A Heterotricyclyl 6-alkylidene-penems as beta epsilontaualpha-lactamase inhibitors
08/03/2005CN1649879A Non-steroidal progesterone receptor modulators
08/03/2005CN1649878A 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof
08/03/2005CN1649876A 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
08/03/2005CN1649875A 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
08/03/2005CN1649871A Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6, 7, 8, 9-tetrahydropydimido[1, 2-a]pyrimidin-4-one derivatives
08/03/2005CN1649869A Azaindoles as inhibitors of c-Jun N-terminal kinases
08/03/2005CN1649867A Novel 1, 2, 3-substituted indolizine derivatives, inhibitors of FGFs, method for making same and pharmaceutical compositions containing same
08/03/2005CN1649864A Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
08/03/2005CN1649863A Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
08/03/2005CN1649857A Hydroxamic acid derivatives
08/03/2005CN1649856A 4-(diarylmethyl)-1-piperazinyl derivatives
08/03/2005CN1649853A Thiazolidinones compound, its preparing method and use as medicine
08/03/2005CN1649849A Tachykinin receptor antagonists
08/03/2005CN1649848A Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF)
1 ... 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 ... 1564